v3.22.4
Segment and Geographic Area Information - Disaggregation of Revenue (Details) - USD ($)
$ in Millions
3 Months Ended 12 Months Ended
Dec. 31, 2022
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Disaggregation of Revenue        
Net revenues   $ 58,054 $ 56,197 $ 45,804
Total net revenues $ 15,121 58,054 56,197 45,804
United States        
Disaggregation of Revenue        
Net revenues   45,713 43,510 34,879
All other        
Disaggregation of Revenue        
Net revenues   4,137 5,019 5,119
Immunology | Humira        
Disaggregation of Revenue        
Net revenues   21,237 20,694 19,832
Immunology | Humira | United States        
Disaggregation of Revenue        
Net revenues   18,619 17,330 16,112
Immunology | Humira | International        
Disaggregation of Revenue        
Net revenues   2,618 3,364 3,720
Immunology | Skyrizi        
Disaggregation of Revenue        
Net revenues   5,165 2,939 1,590
Immunology | Skyrizi | United States        
Disaggregation of Revenue        
Net revenues   4,484 2,486 1,385
Immunology | Skyrizi | International        
Disaggregation of Revenue        
Net revenues   681 453 205
Immunology | Rinvoq        
Disaggregation of Revenue        
Net revenues   2,522 1,651 731
Immunology | Rinvoq | United States        
Disaggregation of Revenue        
Net revenues   1,794 1,271 653
Immunology | Rinvoq | International        
Disaggregation of Revenue        
Net revenues   728 380 78
Hematologic Oncology | Imbruvica        
Disaggregation of Revenue        
Net revenues   4,568 5,408 5,314
Hematologic Oncology | Imbruvica | United States        
Disaggregation of Revenue        
Net revenues   3,426 4,321 4,305
Hematologic Oncology | Imbruvica | International        
Disaggregation of Revenue        
Collaboration revenues   1,142 1,087 1,009
Hematologic Oncology | Venclexta        
Disaggregation of Revenue        
Net revenues   2,009 1,820 1,337
Hematologic Oncology | Venclexta | United States        
Disaggregation of Revenue        
Net revenues   1,009 934 804
Hematologic Oncology | Venclexta | International        
Disaggregation of Revenue        
Net revenues   1,000 886 533
Aesthetics | Botox Cosmetic        
Disaggregation of Revenue        
Net revenues [1]   2,615 2,232 1,112
Aesthetics | Botox Cosmetic | United States        
Disaggregation of Revenue        
Net revenues [1]   1,654 1,424 687
Aesthetics | Botox Cosmetic | International        
Disaggregation of Revenue        
Net revenues [1]   961 808 425
Aesthetics | Juvederm Collection        
Disaggregation of Revenue        
Net revenues [1]   1,428 1,535 718
Aesthetics | Juvederm Collection | United States        
Disaggregation of Revenue        
Net revenues [1]   548 658 318
Aesthetics | Juvederm Collection | International        
Disaggregation of Revenue        
Net revenues [1]   880 877 400
Aesthetics | Other Aesthetics        
Disaggregation of Revenue        
Net revenues [1]   1,290 1,466 760
Aesthetics | Other Aesthetics | United States        
Disaggregation of Revenue        
Net revenues [1]   1,122 1,268 666
Aesthetics | Other Aesthetics | International        
Disaggregation of Revenue        
Net revenues   168 [1] 198 [1] 94
Neuroscience | Botox Therapeutic        
Disaggregation of Revenue        
Net revenues [1]   2,719 2,451 1,387
Neuroscience | Botox Therapeutic | United States        
Disaggregation of Revenue        
Net revenues [1]   2,255 2,012 1,155
Neuroscience | Botox Therapeutic | International        
Disaggregation of Revenue        
Net revenues [1]   464 439 232
Neuroscience | Vraylar        
Disaggregation of Revenue        
Net revenues   2,038 1,728 951
Neuroscience | Vraylar | United States        
Disaggregation of Revenue        
Net revenues [1]   2,037 1,728 951
Neuroscience | Vraylar | International        
Disaggregation of Revenue        
Net revenues   1 0 0
Neuroscience | Duodopa        
Disaggregation of Revenue        
Net revenues   458 511 494
Neuroscience | Duodopa | United States        
Disaggregation of Revenue        
Net revenues   95 102 103
Neuroscience | Duodopa | International        
Disaggregation of Revenue        
Net revenues   363 409 391
Neuroscience | Ubrelvy | United States        
Disaggregation of Revenue        
Net revenues [1]   680 552 125
Neuroscience | Qulipta | United States        
Disaggregation of Revenue        
Net revenues   158 0 0
Neuroscience | Other Neuroscience        
Disaggregation of Revenue        
Net revenues [1]   475 685 539
Neuroscience | Other Neuroscience | United States        
Disaggregation of Revenue        
Net revenues [1]   456 667 528
Neuroscience | Other Neuroscience | International        
Disaggregation of Revenue        
Net revenues [1]   19 18 11
Eye Care | Lumigan/Ganfort        
Disaggregation of Revenue        
Net revenues [1]   514 579 378
Eye Care | Lumigan/Ganfort | United States        
Disaggregation of Revenue        
Net revenues [1]   242 273 165
Eye Care | Lumigan/Ganfort | International        
Disaggregation of Revenue        
Net revenues [1]   272 306 213
Eye Care | Alphagan/Combigan        
Disaggregation of Revenue        
Net revenues [1]   346 529 326
Eye Care | Alphagan/Combigan | United States        
Disaggregation of Revenue        
Net revenues [1]   202 373 223
Eye Care | Alphagan/Combigan | International        
Disaggregation of Revenue        
Net revenues [1]   144 156 103
Eye Care | Restasis        
Disaggregation of Revenue        
Net revenues [1]   666 1,290 787
Eye Care | Restasis | United States        
Disaggregation of Revenue        
Net revenues [1]   621 1,234 755
Eye Care | Restasis | International        
Disaggregation of Revenue        
Net revenues [1]   45 56 32
Eye Care | Other Eye Care        
Disaggregation of Revenue        
Net revenues [1]   1,175 1,169 693
Eye Care | Other Eye Care | United States        
Disaggregation of Revenue        
Net revenues [1]   538 523 305
Eye Care | Other Eye Care | International        
Disaggregation of Revenue        
Net revenues [1]   637 646 388
Other Key Products | Mavyret        
Disaggregation of Revenue        
Net revenues   1,541 1,710 1,830
Other Key Products | Mavyret | United States        
Disaggregation of Revenue        
Net revenues   755 754 785
Other Key Products | Mavyret | International        
Disaggregation of Revenue        
Net revenues   786 956 1,045
Other Key Products | Creon | United States        
Disaggregation of Revenue        
Net revenues   1,278 1,191 1,114
Other Key Products | Linzess/Constella        
Disaggregation of Revenue        
Net revenues [1]   1,035 1,038 667
Other Key Products | Linzess/Constella | United States        
Disaggregation of Revenue        
Net revenues [1]   1,003 1,006 649
Other Key Products | Linzess/Constella | International        
Disaggregation of Revenue        
Net revenues [1]   $ 32 $ 32 $ 18
[1] Net revenues include Allergan product revenues after the acquisition closing date of May 8, 2020.